Tags

Type your tag names separated by a space and hit enter

Evaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation.
Ther Immunol. 1994 Apr; 1(2):77-82.TI

Abstract

Anti-CD5 ricin A chain immunoconjugate (XZ-CD5) is an immunotoxin that inhibits proliferative and cytotoxic responses to alloantigen in vitro and has activity in the treatment of acute graft-vs.-host disease (GVHD). To determine if XZ-CD5 could be used to prevent acute GVHD, 11 adult recipients of HLA-identical allogeneic marrow received XZ-CD5 0.1 mg kg-1 day-1 intravenously with high-dose methyl-prednisolone for 10, 14 or 17 doses early post-transplant. Six additional patients received 17 doses of XZ-CD5 and cyclosporine (CSA). All patients engrafted. Severe capillary leak syndrome was the most common serious toxicity and occurred more frequently in patients receiving CSA (5/5 vs. 3/11, P = 0.03). All evaluable patients developed acute GVHD; 88% had grade II-IV GVHD. Flow cytometric analysis demonstrated a substantial number of circulating CD5+ and CD3+ lymphocytes during and early after administration of XZ-CD5. These results suggest that the immunotoxin did not eliminate alloreactive T cells in this setting.

Authors+Show Affiliations

Section of Bone Marrow Transplantation, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

7584486

Citation

Przepiorka, D, et al. "Evaluation of anti-CD5 Ricin a Chain Immunoconjugate for Prevention of Acute Graft-vs.-host Disease After HLA-identical Marrow Transplantation." Therapeutic Immunology, vol. 1, no. 2, 1994, pp. 77-82.
Przepiorka D, LeMaistre CF, Huh YO, et al. Evaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation. Ther Immunol. 1994;1(2):77-82.
Przepiorka, D., LeMaistre, C. F., Huh, Y. O., Luna, M., Saria, E. A., Brown, C. T., & Champlin, R. E. (1994). Evaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation. Therapeutic Immunology, 1(2), 77-82.
Przepiorka D, et al. Evaluation of anti-CD5 Ricin a Chain Immunoconjugate for Prevention of Acute Graft-vs.-host Disease After HLA-identical Marrow Transplantation. Ther Immunol. 1994;1(2):77-82. PubMed PMID: 7584486.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation. AU - Przepiorka,D, AU - LeMaistre,C F, AU - Huh,Y O, AU - Luna,M, AU - Saria,E A, AU - Brown,C T, AU - Champlin,R E, PY - 1994/4/1/pubmed PY - 1994/4/1/medline PY - 1994/4/1/entrez SP - 77 EP - 82 JF - Therapeutic immunology JO - Ther Immunol VL - 1 IS - 2 N2 - Anti-CD5 ricin A chain immunoconjugate (XZ-CD5) is an immunotoxin that inhibits proliferative and cytotoxic responses to alloantigen in vitro and has activity in the treatment of acute graft-vs.-host disease (GVHD). To determine if XZ-CD5 could be used to prevent acute GVHD, 11 adult recipients of HLA-identical allogeneic marrow received XZ-CD5 0.1 mg kg-1 day-1 intravenously with high-dose methyl-prednisolone for 10, 14 or 17 doses early post-transplant. Six additional patients received 17 doses of XZ-CD5 and cyclosporine (CSA). All patients engrafted. Severe capillary leak syndrome was the most common serious toxicity and occurred more frequently in patients receiving CSA (5/5 vs. 3/11, P = 0.03). All evaluable patients developed acute GVHD; 88% had grade II-IV GVHD. Flow cytometric analysis demonstrated a substantial number of circulating CD5+ and CD3+ lymphocytes during and early after administration of XZ-CD5. These results suggest that the immunotoxin did not eliminate alloreactive T cells in this setting. SN - 0967-0149 UR - https://www.unboundmedicine.com/medline/citation/7584486/Evaluation_of_anti_CD5_ricin_A_chain_immunoconjugate_for_prevention_of_acute_graft_vs__host_disease_after_HLA_identical_marrow_transplantation_ L2 - http://www.diseaseinfosearch.org/result/7171 DB - PRIME DP - Unbound Medicine ER -